Thought about attending, but not much to discuss really - will wait for updates.
Newsletter said it all.
Evolis progressing
Advangen is primed to take advantage of new hair care megatrend
Columbia University study shows FGF5 is crucial regulator of human hair loss
Cxbladder is powering on to become an important test for bladder cancer globally
Celera-Quest reported progress with its clinical validation of LungDx
Fujikura has been diligently working on the validation of the test with assistance from Cellmid and
we expect that the agreement will be signed as soon as costs and quantities can be reliably determined by both parties
Solid progress in the oncology program
New Clinical Trial Director, Sarah Culhane
Thought about attending, but not much to discuss really - will...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1091271 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 656147 | 1 |
View Market Depth
| Last trade - 16.12pm 30/08/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable